FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

International Journal of Molecular Medicine

Volumn 38, Issue 1, 2016, Pages 3-15

  Katoh, Masaru ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

Cholangiocarcinoma; Circulating tumor cells; Clinical sequencing; CXCR4; FOXP3; Gatekeeper mutation; Glioblastoma; Infigratinib; Intra tumor heterogeneity; Ovarian cancer; Peritoneal dissemination

Indexed keywords

AFATINIB; AXITINIB; AZD 4547; CABOZANTINIB; CERITINIB; COLONY STIMULATING FACTOR 1; CRIZOTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOVITINIB; ERDAFITINIB; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 20; FIBROBLAST GROWTH FACTOR RECEPTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 7; GEFITINIB; HEPARAN SULFATE; INFIGRATINIB; LAPATINIB; LENVATINIB; MONOCLONAL ANTIBODY; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEOGLYCAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ENDOTHELIUM CELL; FGFR1 GENE; GENE; GENE SEQUENCE; HEALTH CARE SYSTEM; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOCOMPETENT CELL; LIVER TOXICITY; LUNG CANCER; MISSENSE MUTATION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH CANCER; STROMA CELL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; HOMEOSTASIS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84978880012     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2620     Document Type: Review

References (137)

1. Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134, 2010.
2. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science 298: 1912-1934, 2002.
3. Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79: 34-74, 2014.
4. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL and Wilding G: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23: 5474-5483, 2005.
5. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298-2308, 2011.
6. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, et al: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 56: 5675-5690, 2013.
7. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, et al: Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54: 6342-6363, 2011.
8. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747, 2014.
9. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412, 2009.
10. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245-255, 2011.
11. Chow LQ and Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 25: 884-896, 2007.
12. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J and Schlumberger M: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: 767-772, 2010.
13. Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149, 2005.
14. Katoh M and Nakagama H: FGF receptors: Cancer biology and therapeutics. Med Res Rev 34: 280-300, 2014.
15. Coleman SJ, Bruce C, Chioni AM, Kocher HM and Grose RP: The ins and outs of fibroblast growth factor receptor signalling. Clin Sci (Lond) 127: 217-231, 2014.
16. Ornitz DM and Itoh N: The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4: 215-266, 2015.
17. Katoh M: FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J Invest Dermatol 129: 1861-1867, 2009.
18. Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10: 116-129, 2010.
19. Kelleher FC, O'Sullivan H, Smyth E, McDermott R and Viterbo A: Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis 34: 2198-2205, 2013.
20. Helsten T, Schwaederle M and Kurzrock R: Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: Biologic and clinical implications. Cancer Metastasis Rev 34: 479-496, 2015.
21. Brooks AN, Kilgour E and Smith PD: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18: 1855-1862, 2012.
22. Chang J, Liu X, Wang S, Zhang Z, Wu Z, Zhang X and Li J: Prognostic value of FGFR gene amplification in patients with different types of cancer: A systematic review and meta-analysis. PLoS One 9: e105524, 2014.
23. Parker BC and Zhang W: Fusion genes in solid tumors: An emerging target for cancer diagnosis and treatment. Chin J Cancer 32: 594-603, 2013.
24. Feng S, Zhou L, Nice EC and Huang C: Fibroblast growth factor receptors: Multifactorial-contributors to tumor initiation and progression. Histol Histopathol 30: 13-31, 2015.
25. Liang G, Chen G, Wei X, Zhao Y and Li X: Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev 24: 467-475, 2013.
26. André F and Cortés J: Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat 150: 1-8, 2015.
27. Porta C, Giglione P, Liguigli W and Paglino C: Dovitinib (CHIR258, TKI258): Structure, development and preclinical and clinical activity. Future Oncol 11: 39-50, 2015.
28. Carter EP, Fearon AE and Grose RP: Careless talk costs lives: Fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol 25: 221-233, 2015.
29. Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, et al: Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget 6: 2009-2022, 2015.
30. Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 34: 2167-2177, 2015.
31. Ronca R, Giacomini A, Rusnati M and Presta M: The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin Ther Targets 19: 1361-1377, 2015.
32. Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ and Thompson LM: Fibroblast growth factor receptor 3 interacts with and activates TGF-activated kinase 1 tyrosine phosphorylation and NFB signaling in multiple myeloma and bladder cancer. PLoS One 9: e86470, 2014.
33. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
34. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93, 2010.
35. Cihoric N, Savic S, Schneider S, Ackermann I, Bichsel-Naef M, Schmid RA, Lardinois D, Gugger M, Bubendorf L, Zlobec I, et al: Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer 110: 2914-2922, 2014.
36. Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, von Deimling A, et al: High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer 83: 83-89, 2014.
37. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, et al: The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22: 2109-2119, 2012.
38. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, et al: Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3: 636-647, 2013.
39. Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, et al: Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2. Cancer Res 75: 3139-3146, 2015.
40. Maxmen A: The hard facts. Nature 485: S50-S51, 2012.
41. Ellis MJ and Perou CM: The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 3: 27-34, 2013.
42. Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, Ow SG, Nandi S, Lim CT and Thiery JP: Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget 6: 15578-15593, 2015.
43. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, et al: Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345: 216-220, 2014.
44. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, et al: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15: 267-274, 2014.
45. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, LopezGarcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094, 2010.
46. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50: 1330-1344, 2014.
47. Holbrook JD, Parker JS, Gallagher KT, Halsey WS, Hughes AM, Weigman VJ, Lebowitz PF and Kumar R: Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med 9: 119, 2011.
48. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684, 2012.
49. Jung EJ, Jung EJ, Min SY, Kim MA and Kim WH: Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 43: 1559-1566, 2012.
50. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, et al: FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study. Br J Cancer 110: 967-975, 2014.
51. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, et al: FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19: 2572-2583, 2013.
52. Zhang T, Zhang L, Fan S, Zhang M, Fu H, Liu Y, Yin X, Chen H, Xie L, Zhang J, et al: Patient-derived gastric carcinoma xenograft mouse models faithfully represent human tumor molecular diversity. PLoS One 10: e0134493, 2015.
53. Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, et al: Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma. Clin Cancer Res 21: 4935-4946, 2015.
54. Reintjes N, Li Y, Becker A, Rohmann E, Schmutzler R and Wollnik B: Activating somatic FGFR2 mutations in breast cancer. PLoS One 8: e60264, 2013.
55. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ and Pollock PM: FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 7: e30801, 2012.
56. Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, He J, Palmer G, Yelensky R, Lipson D, et al: Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 27: 271-280, 2014.
57. Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, et al: Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 7: 41-54, 2009.
58. Koika V, Varnavas P, Valavani H, Sidis Y, Plummer L, Dwyer A, Quinton R, Kanaka-Gantenbein C, Pitteloud N, Sertedaki A, et al: Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH). Gene 516: 146-151, 2013.
59. Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, Sykiotis GP, Beenken A, Liu Y, Tommiska J, Hu Y, et al: Congenital hypogonadotropic hypogonadism with split hand/foot malformation: A clinical entity with a high frequency of FGFR1 mutations. Genet Med 17: 651-659, 2015.
60. Jackson CC, Medeiros LJ and Miranda RN: 8p11 myeloproliferative syndrome: A review. Hum Pathol 41: 461-476, 2010.
61. Kumar KR, Chen W, Koduru PR and Luu HS: Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: A case report and review of literature. Am J Clin Pathol 143: 738-748, 2015.
62. Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, Taniwaki M, Matsuda A and Bessho M: Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 61: 8371-8374, 2001.
63. Ren M, Qin H, Kitamura E and Cowell JK: Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models. Blood 122: 1007-1016, 2013.
64. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, et al; St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45: 602-612, 2013.
65. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, et al: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 6: 6087, 2015.
66. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et al: AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72: 2045-2056, 2012.
67. Kwak Y, Cho H, Hur W and Sim T: Antitumor effects and mechanisms of AZD4547 on FGFR2-deregulated endometrial cancer cells. Mol Cancer Ther 14: 2292-2302, 2015.
68. Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, et al: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2: 1118-1133, 2012.
69. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, et al: First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov 5: 424-437, 2015.
70. Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T, et al: The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther 13: 2547-2558, 2014.
71. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, et al: In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11: 3633-3641, 2005.
72. Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, et al: Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci USA 111: E4869-E4877, 2014.
73. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, et al: Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 33: 3401-3408, 2015.
74. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K, et al: A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 10: 2200-2210, 2011.
75. Shah RR and Morganroth J: Update on cardiovascular safety of tyrosine kinase inhibitors: With a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf 38: 693-710, 2015.
76. Gacche RN and Meshram RJ: Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochim Biophys Acta 1846: 161-179, 2014.
77. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C and Dogné JM: Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: A systematic review and meta-analysis. JAMA Oncol: Feb 4, 2016 (Epub ahead of print). doi: 10. 1001/jamaoncol. 2015. 5932.
78. Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol 31: 2205-2218, 2013.
79. Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423-1437, 2013.
80. Junttila MR and de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501: 346-354, 2013.
81. Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et al: Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol 17: 1193-1204, 2015.
82. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, et al: A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2: e39, 2013.
83. Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, et al: FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget 6: 19647-19660, 2015.
84. Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 17: 1359-1370, 2011.
85. Bridges E, Oon CE and Harris A: Notch regulation of tumor angiogenesis. Future Oncol 7: 569-588, 2011.
86. Katoh M: Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med 32: 763-767, 2013.
87. Schmitt J and Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 38: 272-283, 2012.
88. Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer 13: 871-882, 2013.
89. Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, Osei-Owusu P, Hsu J, Zapata N, Liu F, et al: Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci USA 111: 13379-13384, 2014.
90. Xiao L, Yang S, Hao J, Yuan X, Luo W, Jiang L, Hu Y, Fu Z, Zhang Y and Zou C: Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett 359: 148-154, 2015.
91. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL and Sood AK: Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches. Cancer Metastasis Rev 34: 19-40, 2015.
92. Hilbert T and Klaschik S: The angiopoietin/TIE receptor system: Focusing its role for ischemia-reperfusion injury. Cytokine Growth Factor Rev 26: 281-291, 2015.
93. Fagiani E and Christofori G: Angiopoietins in angiogenesis. Cancer Lett 328: 18-26, 2013.
94. Zhou W, Wang G and Guo S: Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 1836: 304-320, 2013.
95. Rostama B, Peterson SM, Vary CP and Liaw L: Notch signal integration in the vasculature during remodeling. Vascul Pharmacol 63: 97-104, 2014.
96. Zhang P, Yan X, Chen Y, Yang Z and Han H: Notch signaling in blood vessels: From morphogenesis to homeostasis. Sci China Life Sci 57: 774-780, 2014.
97. Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y and D'Onofrio A: Anti-VEGF and beyond: Shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today 16: 1052-1060, 2011.
98. Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570, 2011.
99. Talmadge JE and Gabrilovich Di: History of myeloid-derived suppressor cells. Nat Rev Cancer 13: 739-752, 2013.
100. Mantovani A and Sica A: Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237, 2010.
101. Sakaguchi S, Miyara M, Costantino CM and Hafler DA: FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490-500, 2010.
102. Balkwill FR: The chemokine system and cancer. J Pathol 226: 148-157, 2012.
103. Lippitz BE, Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol : e218-e228 2013
104. Condamine T, Ramachandran I, Youn JI and Gabrilovich Di: Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 66: 97-110, 2015.
105. Rivera LB and Bergers G: Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol 36: 240-249, 2015.
106. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, et al: CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61: 1591-1602, 2015.
107. Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X, et al: Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res 17: 141, 2015.
108. Liu L, Ye TH, Han YP, Song H, Zhang YK, Xia Y, Wang NY, Xiong Y, Song XJ, Zhu YX, et al: Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem 33: 633-645, 2014.
109. Hume DA and MacDonald KP: Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119: 1810-1820, 2012.
110. Sieweke MH and Allen JE: Beyond stem cells: Self-renewal of differentiated macrophages. Science 342: 1242974, 2013.
111. Hamilton JA and Achuthan A: Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 34: 81-89, 2013.
112. Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O and Wu L: Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res 75: 4742-4752, 2015.
113. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67, 2011.
114. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W and Wu L: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 73: 2782-2794, 2013.
115. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25: 846-859, 2014.
116. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E and Bergers G: Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep 11: 577-591, 2015.
117. Beenken A and Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
118. Degirolamo C, Sabbà C and Moschetta A: Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15: 51-69, 2016.
119. Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, Hu B, Braddock M, Chen YP, et al: Targeting fibroblast growth factor 19 in liver disease: A potential biomarker and therapeutic target. Expert Opin Ther Targets 19: 675-685, 2015.
120. Pai R, French D, Ma N, Hotzel K, Plise E, Salphati L, Setchell KD, Ware J, Lauriault V, Schutt L, et al: Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci 126: 446-456, 2012.
121. Ge H, Zhang J, Gong Y, Gupte J, Ye J, Weiszmann J, Samayoa K, Coberly S, Gardner J, Wang H, et al: Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem 289: 30470-30480, 2014.
122. Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang S, Andresen J, Stubbs JR and Wacker MJ: FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 307: E426-E436, 2014.
123. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, et al: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22: 1020-1032, 2015.
124. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science 339: 1546-1558, 2013.
125. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, et al: FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 20: 3299-3309, 2014.
126. Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, et al: Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One 8: e77652, 2013.
127. Künstlinger H, Fassunke J, Schildhaus HU, Brors B, Heydt C, Ihle MA, Mechtersheimer G, Wardelmann E, Büttner R and Merkelbach-Bruse S: FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. Oncotarget 6: 20215-20230, 2015.
128. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al: Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346: 256-259, 2014.
129. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, et al: The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526: 263-267, 2015.
130. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, et al: Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346: 1480-1486, 2014.
131. Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR and Cook SJ: Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 32: 3059-3070, 2013.
132. Ang D, Ballard M, Beadling C, Warrick A, Schilling A, O'Gara R, Pukay M, Neff TL, West RB, Corless CL, et al: Novel mutations in neuroendocrine carcinoma of the breast: Possible therapeutic targets. Appl Immunohistochem Mol Morphol 23: 97-103, 2015.
133. Okazaki T and Honjo T: PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19: 813-824, 2007.
134. Sharma P and Allison JP: The future of immune checkpoint therapy. Science 348: 56-61, 2015.
135. Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27: 450-461, 2015.
136. Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14: 561-584, 2015.
137. Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, et al: Development and validation of a scalable next-generation sequencing